Cyclacel Pharma (CYCC) Announces Presentation of Preclinical Data Demonstrating CYC065 Prolongs Survival in MYCN-Addicted Neuroblastoma Models
Tweet Send to a Friend
Cyclacel Pharma (NASDAQ: CYCC) today announced the presentation of preclinical data demonstrating that CYC065, a highly-selective, second-generation cyclin dependent kinase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
